From: Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
Treatment | Mechanism of action | AST/ALT | Liver fat by imaging | Liver histology |
---|---|---|---|---|
Oral | ||||
Insulin-sensitizer | ↓ | ↓*,↔^ | Unchanged | |
PPARγ agonist | ↓ | ↓^ | Improved | |
DPP-4 inhibitor | ↓ | n/a | n/a | |
 Vildagliptin [82] | DPP-4 inhibitor | ↓ | ↓^ | n/a |
 Canagliflozin [90] | Inhibits renal glucose reabsortion | ↓ | n/a | n/a |
Inhibits renal glucose reabsortion | ↓ | n/a | n/a | |
Injectable | ||||
 Exenatide [70] | GLP-1 receptor agonist | ↓ | ↓^ | n/a |
GLP-1 receptor agonist | ↓ | ↓**,^ | Improved |